A cathode active material for a lithium secondary battery includes a lithium metal oxide particle and a thio-based compound formed on at least portion of a surface of the lithium metal oxide particle. The thio-based compound has a double bond that contains a sulfur atom. Chemical stability of the lithium metal oxide particle may be improved and surface residues may be reduced by the thio-based compound.

Disclosed herein is a compound of Formula I, wherein R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.

##STR00001##

Disclosed herein is a compound of Formula I, wherein R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.

##STR00001##

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

What is described is a compound of formula I ##STR00001##
consisting of a compound in which R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or
a pharmaceutically acceptable salt thereof.

What is described is a compound of formula I ##STR00001##
consisting of a compound in which R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or
a pharmaceutically acceptable salt thereof.

What is described is a compound of formula I

##STR00001##

consisting of a compound in which R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

What is described is a compound of formula I

##STR00001##

consisting of a compound in which R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

The composition comprises a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), and comprises 0.00002 to 2.0 parts by mass of the compound (B) with respect to 100 parts by mass of the compound (A),
(R.sub.1COO).sub.nR.sub.2(NCO).sub.m(1)
(R.sub.1COO).sub.nR.sub.2NHC(O)NHR.sub.2(OCOR.sub.1).sub.m(2)
wherein in general formulae (1) and (2), R.sub.1 is an ethylenically unsaturated group having 2 to 7 carbon atoms; R.sub.2 is a (m+n)-valent hydrocarbon group having 1 to 7 carbon atoms and optionally contain an ether group; R.sub.1 and R.sub.2 in the general formula (1) are the same as R.sub.1 and R.sub.2 in the general formula (2); and n and m each represent an integer of one or two.